

An International Journal of Research in AYUSH and Allied Systems

Research Article

A CLINICAL STUDY ON *GUNJATAILA* AND *TILATAILA SHIROABHYANGA* IN THE MANAGEMENT OF *DARUNAKA*

Veerayya R. Hiremath^{1*}, M.V Subramanya², Vasant Patil³

*1HOD PG Dept. of Shalakya Tantra S.V.M.A.M.C.-Ilkal, Karnataka.
²Professor & HOD PG Dept. of Shalakya Tantra. A. A. C Tumkur, Karnataka.
³Professor, PG Dept. of Panchakarma, SSRAMC, Inchal, Karnataka.

| KEYWORDS: | Darunaka, | ABSTRACT |
|-----------------------------|--------------|--|
| Dandruff, <i>Gunjataila</i> | , Tilataila, | Background: Dandruff is an irritative disease of the scalp in which shedding of |
| Shiroabhyanga, | | dead tissue from the scalp with itching sensation is the cardinal feature. It can be |
| | | correlated to Darunaka. The cardinal symptoms of the disease Darunaka are |

*Address for correspondence Dr Veerayya R. Hiremath HOD, PG Dept. of Shalakya Tantra S.V.M.A.M.C.-Ilkal, Karnataka. Mob: 09448544376 Email: <u>drveerurh@yahoo.co.in</u>

INTRODUCTION

Dandruff is an irritative disease of the scalp¹ in which shedding of dead tissue from the scalp with itching sensation is the cardinal feature. It can be correlated to Darunaka² which is one among the Kapalagata Vyaadhi³. The causative factors of Darunaka are not practicing *shiroabhyanga*⁴, Improper cleaning, sleeping during day time, Night vigil, Exposure to dust, hot weather⁵ etc. Now a days, due to increased pollution, busy mechanical life schedule application of impure oils to head, etc. causing high incidence of Darunaka with cardinal symptoms like Kandu (Itching), Rookshata (roughness or dryness of the skin), Twaksphutana (breaking or cracking of the skin) and *Keshachyuti* (falling of hair)⁶, due to the vitiation of Vata and Kapha dosha7. Till now there is no definite cause and solution for this disease. So there is a need to find a safe and effective remedy in the treatment of Darunaka.

Yogaratnakara has mentioned the application of

*Gunjataila*⁸ (i.e., *Gunja, Bhringaraj, Tilataila*) in the treatment of *Darunaka*. The drugs of the yoga are easily available, economical and effective. Therefore, a clinical research work is proposed entitled – "A Clinical Study on *Gunja Taila Shiroabhyanga* in the Management of *Darunaka*" to contribute a solution for the *Darunaka*. The treatment principles mentioned are *Siravyadha* (*Raktamokshana*), *Shiroabhyanga*, *Nasya, Shirolepana, Shiroprakshalana* and *Shirobasti*⁹ which is considered as *Sadya Vyadhi*.¹⁰

OBJECTIVES

adverse drug effects noted at the end of the study.

To compare the effects of *Shiroabhyanga* with *Gunjataila* and *Tila Taila* in the management *Darunaka*

MATERIALS AND METHODS

Kandu (Itching), *Keshachyuti* (falling of hair), *Swapa* (abnormalities of touch sensation), *Rookshata* (roughness or dryness of the skin) and *Twaksphutana* (breaking or cracking of the skin). *Yogaratnakara* has mentioned the application of *Gunjataila* (i.e., *Gunja, Bhringaraj, Tilataila*) in the treatment of *Darunaka*. In the current dermatological practice there is no effective modern remedy for dandruff. Hence the present study is undertaken to find effective and safe alternative to conventional topical anti-dandruff agents. **Objectives:** To compare the effects of *Shiroabhyanga* with *Gunjataila* and *Tila Taila* in the management *Darunaka*. **Materials and methods:** This study was Randomized, open labelled, non-controlled, comparative clinical study. In Group A, *Gujataila shiroabhyanga* and *in* Group-B *Tilataila Shiroabhyanga* was done for thirty days, daily once in the morning, after the completion of treatment, all the patients were advised to attend the O.P.D for two months at regular interval of fifteen days for the follow up study to assess the post effects of treatment. **Results:** Group A showed complete remission in 30%, marked improvement in 30%, moderate 30%

10% mild relief. In patients of Group B only 30% moderate relief and 10% mild

relief from the Darunaka is noticed and 60% of the patients found no relief.

Conclusion: *Gunjataila shiroabhyanga* has higher significant effect in pacifying

the symptoms of Darunaka and marked reduction in clinical symptoms was well

appreciated within one month duration. There was no topical and systemic

Study Design: Randomized, open labelled, non-controlled, comparative clinical study.

Source of Data: The patients who fulfil the Diagnostic criteria for *Darunaka* were selected randomly from the

OPD and IPD of *Shalakyatantra*, S.D.M. Ayurvedic College and Hospital, Hassan.

Study Population: Patients were selected from the Hassan, Karnataka.

Study Sample: Patients of *Darunaka* attending the OPD and IPD of *Shalakya Tantra*, S.D.M. Ayurvedic College and Hospital.

Sample Size: 20

Study Setting: This study was carried on *Darunaka* patients at S.D.M. Ayurvedic College and Hospital, Hassan from year 2004 to 2006.

Trial Drugs

- 1. *Gujataila shiroabhyanga* in Group A.
- 2. Tilataila Shiroabhyanga in Group B.

Collection of Drugs: All the raw materials required for the preparation of *Gunjataila* were procured and purchased from the Department of Dravyaguna, S.D.M.C.A. Hassan.

Method of preparation of *Gunjataila*: The trial medicine was prepared in the department of *Rasa shastra* and *Bhishajya kalpana* as per the *Taila*¹¹ was prepared as per *Snehapaka vidhi*.

Ingredients:

Table 1: Showing the Drugs used in the preparationof the Gunjataila

| S.No. | Drugs | Quantity | |
|-------|-------------|----------------------------|--|
| 01. | Gunjabeeja | 1 part. (to prepare Kalka) | |
| 02. | Tilataila | 4parts | |
| 03. | Bhrungaraja | 16 parts (Swarasa) | |

Diagnostic Criteria:

1) Itching at scalp (*Kandu*)

- 2) Diffuse hair fall (*Keshachyuti*)
- 3) Roughness of scalp (*Rukshata*)
- 4) Scaling of scalp skin (Twaksphutana)

Inclusion criteria

• The patients presenting with classical features of *Darunaka* as mentioned in diagnostic criteria were selected irrespective of Sex and Socio economic status.

Exclusion Criteria

- Associated with other dermatological conditions such as psoriasis etc.
- Patients having Chronic infectious diseases (tuberculosis, leprosy etc.) and metabolic diseases (DM, hypothyroidism etc.)
- Other types of Kapala rogas

Investigations

- 1. Blood for Hb%, TC, DC, ESR.
- 2. Urine for sugar, albumin.

Grouping: Patients were divided into 2 groups. i.e., Group A and Group B.

Group A – *Gunjataila shiroabhyanga* was applied for thirty days, once daily, in the morning.

Group B – *Tilataila shiroabhyanga* was applied for thirty days, once daily, in the morning.

Procedure of Shiroabhyanga

The Shiroabhyanga is one among the Bahrparimarjana chikitsa¹² which is done in following methods¹³: Patient is made to sit in comfortable position by using Sukoshna Gunjataila and Tilataila shiroabhyanga¹⁴ done for respectively A & B group for the duration of 5 Minutes. It is carried out by using tip of the fingers gently massage over the Scalp.

Follow up study: After the completion of treatment, all the patients were advised to attend the O.P.D for two months at regular interval of fifteen days for the follow up study to assess the post effects of treatment.

Criteria for Assessment of Treatment

Assessment of treatment were made before and after the treatment based on,

- 1. Kesha bhoomi Rookshata
- 2. Kandu
- 3. Twaksphutana
- 4. Kesha chyuti

Gradation Index

Showing Gradation Index for assessment criteria

Kesha bhoom Rookshata

| | Absent | : | 0 |
|---|-----------------------------------|---|---|
| | Negligible | : | 1 |
| | Without discomfort on scalp | : | 2 |
| | With discomfort on scalp | : | 3 |
| K | <i>Tandu</i> | | |
| | Absent | : | 0 |
| | Occasionally | : | 1 |
| / | Frequently | : | 2 |
| | Constantly | : | 3 |
| T | <i>wak sphutana</i> (fine flakes) | | |
| | Absent | : | 0 |
| | Visible inside the hair | : | 1 |
| | Visible over the hair | : | 2 |
| | Spreaded over the shoulder | | 3 |
| K | leshachyuti | | |
| | Absent | : | 0 |
| | Occasionally | : | 1 |
| | Moderate loss | : | 2 |
| | Maximum loss | : | 3 |
| | | | |

Overall effect of Therapy

Severity of *Darunaka*: For assessing the severity of *Darunaka* in each patient the above adopted scores were grouped and assessed as follows.

Showing overall effect of therapy

| Grade | Score | |
|----------|-------|-------------|
| Absent | 0 | 0 |
| Mild | 1 | 1 – 4 Score |
| Moderate | 2 | 5 – 8 Score |
| Severe | 3 | > 8 Score |
| | | |

Criteria for Assessment of Overall Effects

Overall effect of the therapy was assessed in terms of complete remission, marked improvement, moderate improvement, and mild improvement and Veerayya R. Hiremath et al. A Clinical Study on Gunjataila and Tilataila Shiroabhyanga in the Management of Darunaka

unchanged is observed by adopting the following criteria. **Complete Remission:** 100% relief in Chief complaints and no recurrence during follow up study were considered as complete remission

Marked Improvement: 75 - 100% improvement in chief complaints is recorded as marked improvement

Moderate Improvement: 50 - 75% improvement in chief complaints is recorded as moderate improvement.

Mild Improvement: 25-50% improvement in chief complaints is considered as mild improvement

Unchanged: Less than 25% reduction in chief complaints or recurrence of the symptoms to the similar extent of severity is noted as recurrence

Statistical analysis of the result

The results having p value less than < 0.05 is considered as statistically significant in this study.

OBSERVATIONS

General Observation: Twenty patients of Darunaka were registered for this clinical study. They were divided into two groups, Gunjataila Shiroabhyanga group (Group A) and *Tilataila Shiroabhyanga* group (Group B) for the purpose of comparative assessment of treatment. Age wise distribution of patients showed that 07 patients (35 %) were in the age group of 10 – 19 yrs, 10 patients (50 %) were in the age group of 20 – 29 years, 02 patients (10 %) were in the age group of 30 - 39 years and 1 patient (05 %) was between the age of group 40-49yrs. Out of 20 cases, the incidence of Darunaka is observed 08 (40%) in the male and 12 (60%) in the female patients. Socio-economic status wise distribution of patients showed that 11 patients (55%) were belonged to lower class, 07 patients were (35%) to middle class and 02 patients were (10 %) to upper class. Out of 20 patients. 05 patients (25 %) were of *Vata kapha*, 07 patients (35 %) were of *Vata pitta prakruti* and 08 patients (40 %) were of Kapha pitta.

| Table 2: Showing | Incidences o | of Symptom | s in Patients |
|-------------------------|--------------|------------|------------------|
| rabie =: ono ming | menaemees | , oy mptom | J III I actorico |

| Symptoms | Group A | | Group B | | Total | | |
|--------------|---------------|-----|-------------|-----|-------------|-----|--|
| | No. of pt's % | | No. of pt's | % | No. of pt's | % | |
| Kandu | 10 | 100 | 10 | 100 | 20 | 100 | |
| Rookshata | 10 | 100 | 10 | 100 | 20 | 100 | |
| Twaksphutana | 10 | 100 | 10 | 100 | 20 | 100 | |
| Keshachyuti | 09 | 90 | 08 | 80 | 17 | 85 | |

Table 3: Showing the 't' test results in reduction of severity of Kandu in Group A group and Group B group after treatment and during follow up

| | | | | | 2 4 6 6 6 6 | - | | | | |
|---------|-------|-----|-------|-----|-------------|--------|--------|----|-------|---------|
| Kandu | Kandu | | score | | Se Ma | S.D of | S.E of | Df | 'ť' | ʻp' |
| | | BT | AT | Red | % | mean | mean | | | |
| Group A | AT | 2.3 | 0.6 | 1.7 | 73 | 0.48 | 0.15 | 9 | 11.13 | < 0.001 |
| | FUI | 2.3 | 0.5 | 1.8 | 78 | 0.42 | 0.13 | 9 | 13.50 | < 0.001 |
| | FU2 | 2.3 | 0.6 | 1.7 | 73 | 0.48 | 0.15 | 9 | 11.13 | < 0.001 |
| Group B | AT | 2.5 | 2.1 | 0.4 | 16 | 0.52 | 0.16 | 9 | 2.45 | < 0.05 |
| _ | FU1 | 2.5 | 2.2 | 0.3 | 12 | 0.48 | 0.15 | 9 | 1.96 | < 0.10 |
| | Fu2 | 2.5 | 2.3 | 0.2 | 8 | 0.42 | 0.13 | 9 | 1.50 | < 0.20 |

Table 4: Showing the 't' test results in reduction of severity of *Rookshata* in Group A group and Group B group after treatment and during follow up

| | | | | | | 0 | - | | | |
|-----------|-----------|-----|-------|-----|----|--------|--------|----|-------|---------|
| Rookshata | Rookshata | | score | | | S.D of | S.E of | Df | 'ť' | ʻp' |
| | | BT | AT | Red | % | mean | mean | | | |
| Group A | AT | 2.4 | 0.7 | 1.7 | 70 | 0.48 | 0.15 | 9 | 11.13 | < 0.001 |
| | FUI | 2.4 | 0.6 | 1.8 | 75 | 0.42 | 0.13 | 9 | 13.50 | < 0.001 |
| | FU2 | 2.4 | 0.7 | 1.7 | 70 | 0.48 | 0.15 | 9 | 11.13 | < 0.001 |
| Group B | AT | 2.4 | 1.8 | 0.5 | 25 | 0.71 | 0.22 | 9 | 2.29 | < 0.05 |
| | FU1 | 2.4 | 2 | 0.4 | 16 | 0.52 | 0.22 | 9 | 2.45 | < 0.05 |
| | Fu2 | 2.4 | 2.1 | 0.3 | 12 | 0.48 | 0.15 | 9 | 1.96 | < 0.10 |

Table 5: Showing the 't' test results in reduction of severity of Twaksphutana in Group A group and Group B group after treatment and during follow up

| Twak Sphut | Twak Sphutana | | score | | | S.D of | S.E of | Df | 'ť | ʻp' |
|------------|---------------|-----|-------|-----|----|--------|--------|----|------|---------|
| | | BT | AT | Red | % | mean | mean | | | |
| Group A | AT | 1.7 | 0.4 | 1.3 | 76 | 0.48 | 0.15 | 9 | 8.51 | < 0.001 |
| | FUI | 1.7 | 0.3 | 1.4 | 82 | 0.52 | 0.16 | 9 | 8.57 | < 0.001 |
| | FU2 | 1.7 | 0.4 | 1.3 | 76 | 0.48 | 0.15 | 9 | 8.51 | < 0.001 |
| Group B | AT | 1.8 | 1.2 | 0.6 | 33 | 0.70 | 0.22 | 9 | 2.71 | < 0.025 |
| _ | FU1 | 1.8 | 1.3 | 0.5 | 27 | 0.71 | 0.22 | 9 | 2.24 | < 0.05 |
| | Fu2 | 1.8 | 1.4 | 0.4 | 22 | 0.70 | 0.22 | 9 | 1.81 | >0.1 |

AYUSHDHARA, 2016;3(4):792-796

| after treatment and turing follow up | | | | | | | | | | |
|--------------------------------------|-------------|-----|-------|-----|----|--------|--------|----|------|---------|
| Keshachyut | Keshachyuti | | score | | | S.D of | S.E of | Df | 'ť | ʻp' |
| | | BT | AT | Red | % | mean | mean | | | |
| Group A | AT | 1.4 | 0.5 | 0.9 | 64 | 0.32 | 0.10 | 9 | 9.00 | < 0.001 |
| | FUI | 1.4 | 0.4 | 1 | 71 | 0.47 | 0.15 | 9 | 6.71 | < 0.001 |
| | FU2 | 1.4 | 0.5 | 0.9 | 64 | 0.32 | 0.10 | 9 | 9.00 | < 0.001 |
| Group B | AT | 1.4 | 0.8 | 0.6 | 42 | 0.70 | 0.22 | 9 | 2.71 | < 0.025 |
| | FU1 | 1.4 | 0.8 | 0.6 | 42 | 0.70 | 0.22 | 9 | 2.71 | < 0.025 |
| | Fu2 | 1.4 | 0.9 | 0.5 | 35 | 0.71 | 0.22 | 9 | 2.24 | < 0.05 |

Table 6: Showing the 't' test results in reduction of severity of Keshachyuti in Group A group and Group B groupafter treatment and during follow up

Table 7: Showing the 't' test results in reduction of severity of Darunaka in Group A group and Group B groupafter treatment and during follow up

| Severity of | Severity of Darunak | | score | | | S.D of | S.E of | Df | ʻť | ʻp' |
|-------------|---------------------|-----|-------|-----|----|--------|--------|----|-------|---------|
| | | BT | AT | Red | % | mean | mean | | | |
| Group A | AT | 2.4 | 0.8 | 1.6 | 66 | 0.52 | 0.16 | 9 | 9.80 | < 0.001 |
| | FUI | 2.4 | 0.7 | 1.7 | 70 | 0.48 | 0.15 | 9 | 11.13 | < 0.001 |
| | FU2 | 2.4 | 0.8 | 1.6 | 66 | 0.52 | 0.16 | 9 | 9.80 | < 0.001 |
| Group B | AT | 2.4 | 2 | 0.4 | 16 | 0.52 | 0.16 | 9 | 2.45 | < 0.05 |
| - | FU1 | 2.4 | 2.1 | 0.3 | 12 | 0.48 | 0.15 | 9 | 1.96 | < 0.10 |
| | Fu2 | 2.4 | 2.2 | 0.2 | 08 | 0.42 | 0.13 | 9 | 1.50 | < 0.20 |

Table 8: Showing the percentage of improvement in the symptoms of Darunaka in Group A and Group B groupsafter treatment and during follow ups

| Percentage of Relief | | Group | Α | Group B | | | |
|----------------------|----|-------|-----|---------|-----|-----|--|
| | AT | FU1 | FU2 | AT | FU1 | FU2 | |
| Kandu | 73 | 78 | 73 | 16 | 12 | 08 | |
| Rookshata | 70 | 75 | 70 | 25 | 16 | 12 | |
| Twaksphutana | 76 | 82 | 76 | 33 | 27 | 22 | |
| Kesha chyuti | 64 | 71 | 64 | 42 | 42 | 35 | |

Table 9: Showing over all percentage of improvement in the patients of Group A and Group B groups

| Overall % ^{age} | Group A | | | | | Group B | | | | |
|---------------------------------|---------|-----|-----|-----|-----|---------|-----|-----|-----|-----|
| Relief | AT | FU1 | FU2 | FU3 | FU4 | AT | FU1 | FU2 | FU3 | FU4 |
| Complete Relief | 30 | 30 | 30 | 30 | 30 | 00 | 00 | 00 | 00 | 00 |
| Marked Relief | 30 | 30 | 30 | 30 | 30 | 00 | 00 | 00 | 00 | 00 |
| Moderate Relief | 30 | 40 | 40 | 10 | 30 | 30 | 30 | 20 | 20 | 20 |
| Mild Relief | 10 | 00 | 00 | 00 | 10 | 10 | 10 | 10 | 10 | 00 |
| No Relief | 00 | 00 | 00 | 00 | 00 | 60 | 60 | 70 | 70 | 80 |

DISCUSSION

Darunaka is generally correlated to Dandruff or Pytiriasis capitis, it resembles more accurately with the signs and symptoms of dry variety of Pytiriasis capitis. Few of the significantly resembling factors are *Twak* Sphutana (scales are dry, fine, white and fall freely on shoulders), *Rookshata* (hair are dry and fine), *Kandu* (mild itching). But hair fall has not been directly mentioned in the modern classics; Even then we can consider Kasha chyuti as a reason of *Rookshata* of hairs.

Effect on *Kandu*: Severity of *Kandu* is significantly reduced after treatment in *Gunjataila* group. The reduction of *Kandu* within the groups was Group A 73% and Group B 16%. The effects of Group A group was significant at level of p<0.001. It indicates that, *Gunjataila Shiroabhyanga* is better than *Tilataila Shiroabhyanga*. It is due to the effect of *Gunja* and *Bhrungaraja* present in the *Gunjataila*

Effect on *Rookshata*: Severity of *Rookshata* of *Kapala pradesha* is significantly reduced after treatment in Group A group with 70% of efficacy and Group B group

showed only 25% efficacy. The effect of Group A group was significant at level of p<0.001. This data indicates that *Gunjataila shiroabhyanga* is more effective in reducing severity of *Rookshata*.

Effect on Shedding of scales: Severity of shedding of Scales is significantly reduced after treatment Group A group with 76% of efficacy whereas Group B group showed only 33% of efficacy in reducing the shedding of scales. The effect of Group A group was significant at the level of p<0.001. This data indicates that *Gunjataila* is more effective in reducing severity of shedding of Scales than *Tilataila*.

Effect on *Keshachyuti*: Severity of Falling of hairs is significantly reduced after treatment in Group A group with 64% of efficacy and Group B group showed a lesser efficacy of 42%. The effect of Group A group was significant at level of p<0.001. This data indicates that *Gunjataila Shiroabhyanga* is more effective in reducing severity of hair fall.

AYUSHDHARA | July - August 2016 | Vol 3 | Issue 4

Discussion on Overall Effects of the Therapy

Consideration of overall effect of therapies after one month of treatment showed that in Group A group complete remission was found in 30% (6 pt's), marked improvement was found in 30% (6 pt's), moderate 30% (6 pt's) and 10% (2 pt's) mild relief. In patients of Group B group only 30% (6 pt's) moderate relief and 10% (2 pt's) mild relief from the *Darunaka* is noticed and 60% (12 pt's) of the patients found no relief.

Follow Up

On the basis of the above results it can be concluded that *Gunjataila shiroabhyanga* not only provide cure to the patients of *Darunaka*, but it also prevents its recurrence. In the second follow up the recurrence in one patient of Group A might have occurred due to indulgence in *Nidana* again and not following the advice.

Comparison of Effects of Therapies

Gunjataila Shiroabhyanga: Shiroabhyanga with Gunjataila provided better relief in all symptoms of Darunaka especially in Kandu, Rookshata, Twaksphutana and Keshachyuti.

Tilataila Shiroabhyanga: Shiroabhyanga with Tilataila provided moderate relief in all symptoms of Darunaka but 60% of the patients didn't show any relief. The above discussions infer that in Group A group the effect of the drug is higher than Group B group. Hence from the above results it may be abstracted that *Shiroabhyanga* with *Gunjataila* provided better overall effect to the patients of Darunaka with highly significant statistical values than *Shiroabhyanga* with *Tilataila*.

CONCLUSION

Group A group showed complete remission in 30%, marked improvement in 30%, moderate 30% and 10% mild relief. In patients of Group B group only 30% moderate relief and 10% mild relief from the *Darunaka* 1 is noticed and 60% of the patients found no relief. *Gunjataila shiroabhyanga* has higher significant effect in pacifying the symptoms of *Darunaka* and marked reduction in clinical symptoms was well appreciated 1 within one month duration. There was no topical and systemic adverse drug effects noted at the end of the study.

REFERENCES

- Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 1-4160-2999-0.
- 2. Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 23, Shloka no 1-2, Nirmala Hindi commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1050.
- 3. Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 23, Shloka no 20, Nirmala Hindi

commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1053.

- 4. Prof.Jyotir Mitra, Astanga Sagraham by Indu, Uttarasthana, Reprint Edition 2006, Chapter no 17, Shloka no 18, Sasilekha Hindi commentary, Varanasi: Chaukhambha Sanskrit Series Office, Page no 716.
- 5. Acharya Yadava Sharma, Charaka Samhita, Sutrasthana, Reprint edition 2011, Chapter no 17, Shloka no 7-10, Ayurveda Dipika Hindi commentary, Varanasi: Chaukhambha Sanskrit Samsthana; 2011. page 256-257.
- 6. Vaidya LakshmipatiShastri, Yogaratnakara, Uttararda, Chapter Kshdraroganidana, Shloka no 30, Vidyotini commentary, Varanasi : Chaukhambha Prakashan, Page no 272.
- Vaidya Lakshmipati Shastri, Yogaratnakara, Uttararda, Chapter Kshudraroga chikitsa, Shloka no 1, Vidyotini Hindi commentary, Varanasi : Chaukhambha Prakashan, Page no 280.
- 8. Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 23, Shloka no 23, Nirmala Hindi commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1053.
- 9. Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 24, Shloka no 25-27, Nirmala hindi commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1060.
- Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 23, Shloka no 31, Nirmala Hindi commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1054.
- Bhavaprakash Nighantu, Uttarardha, by Bhishagratna Pandit Shri Bramha Shankar Mishra;
 65:19 Chaukhamba Sanskrita Samsthana, Varanasi, 9th Edn, 2005. 694 p
- 12. Acharya Yadava Sharma, Charaka Samhita, Sutrasthana, Reprint edition 2011, Chapter no 11, Shloka no 55, Ayurveda Dipika Hindi commentary, Varanasi: Chaukhambha Sanskrit Samsthana; 2011. page 184.
- 13. Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 22, Shloka no 24, Nirmala Hindi commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1038.
- 14. Dr.Brahmanandtripathi, Astangahrudayam by Shrimadvaghbhata, Uttarasthana, Reprint Edition 2013, Chapter no 22, Shloka no 23, Nirmala Hindi commentary, Delhi: Chaukhambha Sanskrit Prathisthan, Page no 1038.

Cite this article as:

Veerayya R. Hiremath, M.V Subramanya, Vasant Patil. A Clinical Study on Gunjataila and Tilataila Shiroabhyanga in the Management of Darunaka. AYUSHDHARA, 2016;3(4):792-796. Source of support: Nil, Conflict of interest: None Declared

AYUSHDHARA | July - August 2016 | Vol 3 | Issue 4